EP4036097A1 — Ip4-4,6 substituted derivative compounds
Assigned to Sanifit Therapeutics SA · Expires 2022-08-03 · 4y expired
What this patent protects
The present invention provides IP4-4,6 substituted derivatives, their methods of synthesis and their uses. In some aspects, the IP4-4,6 derivative is a compound of formula I wherein R<sub>1</sub>, R<sub>3</sub>, R<sub>7</sub>, and R<sub>1…
USPTO Abstract
The present invention provides IP4-4,6 substituted derivatives, their methods of synthesis and their uses. In some aspects, the IP4-4,6 derivative is a compound of formula I wherein R<sub>1</sub>, R<sub>3</sub>, R<sub>7</sub>, and R<sub>11</sub> are OPO<sub>3</sub><sup>2-</sup>, and R<sub>5</sub> and R<sub>9</sub> are selected from the group consisting of -O(Alkyl)<sub>n</sub>X, -O(Alkyl)<sub>y</sub>Cy(Alkyl<sub>2</sub>)<sub>y</sub>-Z, -O(Alkyl)<sub>y</sub>A(Alkyl)<sub>y</sub>-Z', and their thiophosphate analogs. Also provided are methods, pharmaceutical compositions and formulations, methods of use, articles of manufacture, and kits for the treatment of diseases and conditions such as pathological crystallization-related diseases and conditions.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.